Clinical Trial: PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC

U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07697859) titled 'PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC' on July 02.

Brief Summary: Although immunotherapy combined with chemotherapy has become the first-line standard regimen for advanced esophageal squamous cell carcinoma (ESCC) and improved clinical outcomes in advanced patients, the prognosis of patients with esophageal cancer remains unsatisfactory, with a 5-year overall survival rate below 20%. As an effective modality for local disease control, local radiotherapy has no established optimal sequencing schedule when combined with systemic therapy. The timing of radiotherapy intervention may dir...